Pharming Group N.V. PHARM
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Pharming Group N.V. shares you hold and we'll calculate your dividend payments:
Sign up for Pharming Group N.V. and we'll email you the dividend information when they declare.
Add Pharming Group N.V. to receive free notifications when they declare their dividends.
Your account is set up to receive Pharming Group N.V. notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Pharming Group N.V. dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0¢ | — |
| 2007 | 0.0¢ | 0% |
| 2008 | 0.0¢ | 0% |
| 2009 | 0.0¢ | 0% |
| 2010 | 0.0¢ | 0% |
| 2011 | 0.0¢ | 0% |
| 2012 | 0.0¢ | 0% |
| 2013 | 0.0¢ | 0% |
| 2014 | 0.0¢ | 0% |
| 2015 | 0.0¢ | 0% |
| 2016 | 0.0¢ | 0% |
| 2017 | 0.0¢ | 0% |
| 2018 | 0.0¢ | 0% |
| 2019 | 0.0¢ | 0% |
| 2020 | 0.0¢ | 0% |
| 2021 | 0.0¢ | 0% |
| 2022 | 0.0¢ | 0% |
| 2023 | 0.0¢ | 0% |
| 2024 | Sign Up Required | |
Pharming Group N.V. Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 30 May 2023
- 52 Week Low
- 0.0% on 30 May 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Pharming Group N.V.
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Netherlands
- Share Price
- €0.90 (yesterday's closing price)
- Shares in Issue
- 671 million
- Market Cap
- €604mn
- 0
- Market Indices
- none
